41:11Biotech's New Normal: Pharma M&A, AI & Leadership in 2026 | Steve St. Onge
629 views · 2d ago · 41:11
Guest: Steve St. Onge
Biotech's New Normal: Pharma M&A, AI & Leadership in 2026 | Steve St. Onge Michael Pietrack speaks with Steve St. Onge, PharmD, MBA, Chief Business Officer at Claromedics Biosciences, about the changing biotech landscape in 2026. Explore biotech funding challenges, pharma M&A, IPOs, venture capital, AI innovation, and the leadership skills needed to navigate uncertainty in the pharmaceutical industry.
Topics: The Mentors Who Shaped Steve's Leadership Journey · Thinking Like an Executive: Enterprise-Level Leadership · Making Strategic Decisions and Evaluating Trade-Offs · What Caused the Biotech Financing Downturn? · The Biotech Funding Boom and Market Correction · How the Pharma M&A Slowdown Impacted Biotech
▶️ Mentioned videos: Video on youtube.com · Video on youtube.com




